Search clinical trials for: juvenile myelomonocytic leukemia

Total 9563 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome

United States
Kirsten Grønbæk
Odense University Hospital; Karolinska University Hospital; Zealand University... and other collaborators

Recruiting

Combining Active and Passive DNA Hypomethylation (EVI-3)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Denmark, Sweden
Omar Aljitawi

Recruiting

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Atypical Chronic Myeloid Leukemia | Chronic Monocytic Leukemia

United States
Nerviano Medical Sciences

Recruiting

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Italy, Spain, France
Dana-Farber Cancer Institute

Recruiting

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Myeloproliferative Neoplasms

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 10-19 Percent of Bone Marrow Nucleated Cells and other conditions

United States
Shenzhen Second People's Hospital

Recruiting

Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy

Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia

China
Johns Hopkins All Children's Hospital

Recruiting

Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Juvenile Myelomonocytic Leukemia | Mixed Phenotype Acute Leukemia

United States
National Cancer Institute (NCI)

Not yet recruiting

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory High Risk Myelodysplastic Syndrome
Children's Hospital of Philadelphia

Recruiting

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Juvenile Myelomonocytic Leukemia | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Acute Leukemia | Mixed Lineage Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | IDH2 Gene Mutation | Acute Bilineal Leukemia | Acute Biphenotypic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States
Jacqueline Garcia, MD
National Institutes of Health (NIH)

Recruiting

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Hematopoietic Stem Cell Transplant | MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable)

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Celgene

Recruiting

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome With Excess Blasts | IDH2 Gene Mutation | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 20-30 Percent of Bone Marrow Nucleated Cells

United States
Masonic Cancer Center, University of Minnesota

Recruiting

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Lymphoma | Follicular Lymphoma | Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Juvenile Myelomonocytic Leukemia | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Acute Leukemia | Mantle-Cell Lymphoma | Chronic Myelogenous... and other conditions

United States
BioLite, Inc.

Not yet recruiting

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Myelodysplastic Syndrome (MDS)
St. Jude Children's Research Hospital

Recruiting

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Myeloid Sarcoma | Chronic Myeloid Leukemia (CML) | Non-Hodgkin Lymphoma (NHL) | Juvenile Myelomonocytic Leukemia (JMML)

United States
University Health Network, Toronto

Recruiting

Myeloproliferative Neoplasms (MPNs) Patient Registry

Neoplasms | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Leukemia, Myelomonocytic, Chronic | Leukemia, Myelomonocytic, Juvenile | Myelodysplastic-Myeloproliferative Diseases | Mastocytosis | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | Chronic Eosinophilic Leukemia-not...

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Personalized NK Cell Therapy in CBT

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Myelodysplastic Syndrome... and other conditions

United States
Diane George

Recruiting

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Chronic Myeloid Leukemia (CML) | Juvenile Myelomonocytic Leukemia (JMML) | Lymphoma (Hodgkin's and Non-Hodgkin's)

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Anemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2 | Myelodysplastic Syndrome With Excess Blasts-1 | Myelodysplastic Syndrome/Acute Myeloid Leukemia

Canada, United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia With Multilineage Dysplasia | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Blasts 20-30 Percent of Peripheral Blood White Cells | IPSS Risk Category Intermediate-2

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Suspended

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Recurrent Acute Lymphoblastic... and other conditions

United States
M.D. Anderson Cancer Center

Active, not recruiting

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States
Astex Pharmaceuticals, Inc.

Enrolling by invitation

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States, Spain, Canada, Austria, Slovakia, Bulgaria, Hungary
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

China, Czechia, Japan, Saudi Arabia, Taiwan, Turkey, Germany, Spain, Netherlands, Italy, Singapore, Australia, Austria, France, United Kingdom, Korea, Republic of, Thailand, Israel, Belgium, Canada, Switzerland, Lithuania, Russian Federation and more
Amgen

Completed

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Higher Risk Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Acute Myeloid Leukemia | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative... and other conditions

United States
Takeda
Takeda Development Center Americas, Inc.

Active, not recruiting

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)

Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic | Myelodysplastic Syndrome

Australia, United States, Canada, Spain, Belgium, France, Czechia, Italy, Korea, Republic of, Israel, Brazil, China, Germany, Turkey, Japan, Greece, Poland, United Kingdom, Russian Federation, Mexico
Indiana University

Withdrawn

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia, Adult | Bone Marrow Transplant Complications

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (DHODH)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United Kingdom, France, Korea, Republic of, Spain
Rigshospitalet, Denmark
Odense University Hospital; University of Copenhagen; Imperial College London; University... and other collaborators

Active, not recruiting

Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies (EVITA)

Myelodysplastic Syndromes | Cytopenia | Chronic Myelomonocytic Leukemia-1

Denmark, United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Precancerous/Nonmalignant Condition
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid... and other conditions

United States
Roswell Park Cancer Institute

Active, not recruiting

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Acute Myeloid Leukemia | Polycythemia Vera | Myelofibrosis | Chronic Myelomonocytic Leukemia | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Secondary Acute Myeloid Leukemia | Sickle Cell Disease | Myelodysplastic Syndrome | Plasma Cell Myeloma | Chronic Granulomatous... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome

United States
Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed

Registry on Hypomethylating Agents in Myeloid Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Austria, Croatia
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Active, not recruiting

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

Leukemia | Chronic Myelomonocytic Leukemia

United States
Fred Hutchinson Cancer Center
HighPass Bio, Inc.

Suspended

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Acute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Adult Acute Myeloid Leukemia in Remission | Myelodysplastic Syndrome | Adult Acute Lymphoblastic Leukemia in Remission | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic...

United States
M.D. Anderson Cancer Center

Active, not recruiting

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic/Myeloproliferative Neoplasm | Refractory Myelodysplastic/Myeloproliferative Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Hematopoietic and Lymphoid Cell Neoplasm | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States
Massachusetts General Hospital
Celgene

Completed

IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia

United States
M.D. Anderson Cancer Center
Syros Pharmaceuticals Inc.

Withdrawn

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

United States
Zachariah Michael DeFilipp
Regimmune Corporation

Active, not recruiting

Haplo Peripheral Blood Sct In GVHD Prevention

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | AML | Non Hodgkin Lymphoma | MDS | Myeloproliferative Disorder | GVHD | Graft Vs Host Disease | ALL | CMML | Blood Stem Cell Transplant Failure | MPN | Chemosensitive Hodgkin Lymphoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

FLT3 Gene Mutation Negative | FLT3 Internal Tandem Duplication Positive | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic...

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult Acute... and other conditions

United States

Search clinical trials for: juvenile myelomonocytic leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations